Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-11-16
2001-11-13
Rotman, Alan L. (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S318000, C514S319000, C514S326000, C514S330000, C514S331000, C514S340000, C514S354000, C514S408000, C514S422000, C514S423000, C514S426000, C514S428000, C514S438000, C514S444000, C514S447000, C514S448000, C514S472000, C514S581000, C548S557000, C548S567000, C549S069000, C549S076000, C549S480000, C549S491000, C549S496000, C564S019000, C564S020000, C564S021000
Reexamination Certificate
active
06316467
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to compounds useful in elevating high density lipoprotein, the “good” cholesterol. Compounds of this invention increase plasma levels of HDL in a cholesterol fed rat model and as such these compounds may be useful for treating diseases such as atherosclerosis.
BACKGROUND OF THE INVENTION
It is widely beleived that HDL is a “protective” lipoprotein [Gloria Lena Vega and Scott Grundy, Current Opinion in Lipidology, 7, 209-216 (1996)] and that increasing plasma levels of HDL may offer a direct protection against the development of atherosclerosis. Numerous studies have demonstrated that both the risk of coronary heart disease (CHD) in humans and the severity of experimental atherosclerosis in animals are inversely correlated with serum HDL cholesterol (HDL-C) concentrations (Russ et al.,
Am. J. Med
., 11 (1951) 480-493; Gofman et al,
Circulation
, 34 (1966) 679-697; Miller and Miller,
Lancet
, 1 (1975) 16-19; Gordon et al.,
Circulation
, 79 (1989) 8-15; Stampfer et al.,
N. Engl. J. Med
., 325(1991) 373-381; Badimon et al.,
Lab. Invest
., 60(1989) 455-461). Atherosclerosis is the process of accumulation of cholesterol within the arterial wall which results in the occlusion, or stenosis, of coronary and cerebral arterial vessels and subsequent myocardial infarction and stroke. Angiographical studies have shown that elevated levels of some HDL particles in humans appears to be correlated to a decreased number of sites of stenosis in the coronary arteries of humans (Miller et al.,
Br. Med. J
., 282 (1981) 1741-1744).
There are several mechanisms by which HDL may protect against the progression of atherosclerosis. Studies in vitro have shown that HDL is capable of removing cholesterol from cells (Picardo et al.,
Arteriosclerosis
, 6 (1986) 434-441). Data of this nature suggest that one antiatherogenic property of HDL may lie in its ability to deplete tissues of excess free cholesterol and eventually lead to the delivery of this cholesterol to the liver (Glomset,
J. Lipid Res
., 9 (1968) 155-167). This has been supported by experiments showing efficient transfer of cholesterol from HDL to the liver (Glass et al.,
Circulation
, 66 (
Suppl. II
)(1982) 102; MacKinnon et al.,
J. Biol. Chem
., 261 (1986) 2548-2552). In addition, HDL may serve as a reservoir in the circulation for apoproteins necessary for the rapid metabolism of triglyceride-rich lipoproteins (Grow and Fried,
J. Biol. Chem
., 253 (1978) 8034-8041; Lagocki and Scanu,
J. Biol. Chem
, 255 (1980) 3701-3706; Schaefer et al.,
J Lipid Res
., 23 (1982) 1259-1273). Accordingly, agents which increase HDL cholesterol concentrations are useful as anti-atherosclerotic agents, particularly in the treatment of dyslipoproteinemias and coronary artery disease.
Takagi et al, U.S. Pat. No. 5,608,109, discloses agricultural and horticultural insecticidal compounds according to formula A below where Ar and R
2
is optionally substituted phenyl, R
1
and R
3
are independently hydrogen, alkyl, alkenyl or alkynyl, and R
4
and R
5
are independently hydrogen or alkyl.
BRIEF DESCRIPTION OF THE INVENTION
The compounds of this invention which elevate plasma levels of HDL cholesterol have the general structure A
wherein:
R
1
, R
2
, and R
3
are independently hydrogen, C
1
-C
6
alkyl, phenyl or —(CH
2
)
1-6
phenyl where phenyl is optionally substituted by halogen, cyano, nitro, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, trifluoromethyl, C
1
-C
6
alkoxycarbonyl, —CO
2
H or OH;
R
4
and R
5
are independently hydrogen, C
1
-C
10
alkyl, C
3
-C
8
cycloalkyl, —(CH
2
)
0-6
Ar
1
where Ar
1
is phenyl, naphthyl, furanyl, pyridinyl or thenyl and Ar
1
can be optionally substituted by halogen, cyano, nitro, C
1
-C
6
alkyl, phenyl, C
1
-C
6
alkoxy, phenoxy, trifluoromethyl, C
1
-C
6
alkoxycarbonyl, —CO
2
H or OH, or R
4
and R
5
together with the nitrogen to which R
4
and R
5
are attached form a ring containing 4-7 carbon atoms;
and Ar is phenyl, naphthyl, furanyl, pyridinyl or thienyl which may be optionally substituted by halogen, cyano, nitro, C
1
-C
6
alkyl, C
3
-C
6
cycloalkyl, phenyl, C
1
-C
6
alkoxy, phenoxy, trifluoromethyl, C
1
-C
6
alkoxycarbonyl, —CO
2
H or OH; with the proviso that Ar and R
2
cannot simultaneously be optionally substituted phenyl when the R
1
and R
3
are independently hydrogen or alkyl.
The compounds are tested in vivo in rats fed cholesterol-augmented rodent chow for 8 days according to the test protocol and blood from the rats analyzed for HDL cholesterol.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of this invention are prepared by reacting 4-oxo-4-arylbutyric acid amides with an appropriately substituted thiosemicarbazide according to Scheme I. The intermediate 4-oxo-4arylbutyric acid amides are conveniently prepared by the routes shown in Scheme II by reacting an amine of the formula HNR
4
R
5
with either a 4-aryl-4-oxo-butyric acid or a &ggr;-aryl-&ggr;-butyrolactone. Specific examples are given in the Experimental Section.
Scheme I: Preparation of title compounds.
Scheme II: Preparation of intermediate 4-oxo-4-phenylbutyric acid amides.
(1) Route A to Ketoamide 1
(2) Route B to Ketoamide 1
REFERENCES:
patent: 3826841 (1974-07-01), Yamamoto et al.
patent: 5608109 (1997-03-01), Takagi et al.
Vega et al.,Current Opinion in Lipidology, 7:209-216 (1996).
Barr et al.,Am. J. Med., 11:480-493 (1951).
Gofman et al.,Circulation, 34:679-697 (1966).
Miller and Miller,Lancet, 1:16-19 (1975).
Gordon et al.,Circulation, 79:8-15 (1989).
Stampfer et al.,N. England J. Med., 325:373-381 (1991).
Badimon et al.,Lab. Invest., 60:455-461 (1989).
Miller et al.,Br. Med. J., 282:1741-1744 (1981).
Picardo et al.,Arteriosclerosis., 6:434-441 (1986).
Glomset,J. Lipid Res., 9:155-167 (1968).
Glass et al.,Circulation, vol. 66, Suppl. II 102 (1982).
MacKinnon et al.,J. Biol. Chem., 261:2548-2552 (1986).
Grow and Fried,J. Biol. Chem., 253:8034-8041 (1978).
Lagocki and Scanu.,J. Biol. Chem., 255:3701-3706 (1978).
Schaefer et al.,J. Lipid Res., 23:1259-1273 (1982).
American Home Products Corporation
Covington Raymond
Nagy Michael R.
Rotman Alan L.
LandOfFree
Elevation of HDL cholesterol by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Elevation of HDL cholesterol by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Elevation of HDL cholesterol by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2598538